TRV734 explained

TRV734 is a drug developed by Trevena Inc which acts as a biased agonist at the μ-opioid receptor, selective for activation of the G-protein signalling pathway over β-arrestin 2 recruitment. It is closely related to oliceridine and has a similar pharmacological profile, but unlike oliceridine which has to be injected, TRV734 is suitable to be administered orally.^[1]

See also

• PZM21
• SHR9352
• SR-17018
• Tegileridine

Notes and References

1. James IE, Skobieranda F, Soergel DG, Ramos KA, Ruff D, Fossler MJ . A First-in-Human Clinical Study With TRV734, an Orally Bioavailable G-Protein-Biased Ligand at the μ-Opioid Receptor . Clinical Pharmacology in Drug Development . 9 . 2 . 256–266 . February 2020 . 31286645 . 10.1002/cpdd.721 . 195843184 .